In Europe, it is estimated that the annual incidence of cutaneous T-cell lymphoma (CTCL) is approx. 52 new cases per million, affecting around 240 people per million at any one time.In this study aims to better understand the predicted OS for advanced M F and SS patients treated with mogamulizumab or vorinostat.Results from the MAIC using MAVORIC and ANCLD data suggest that mogamulizumab can improve OS in patients with pre-treated MF and SS, although the difference did not reach statistical signifi cance probably due to the small patient numbersThis study aims to better understand the predicted OS for advanced M F and SS patients treated with mogamulizumab or vorinostat.